°øÁö»çÇ×

´ëÇѾϿ¬±¸Àç´Ü Á¦ 9 ȸ ¡®±èÁøº¹¾Ï¿¬±¸»ó¡¯ °ø¸ð
ÀÛ¼ºÀÚ
ÇÐȸ°ü¸®ÀÚ
÷ºÎÆÄÀÏ
ȨÆäÀÌÁö
http://koreanfcr.or.kr/
ÀÛ¼ºÀÏ
2014-09-23
Á¶È¸
1543
±¹³» ¾Ï ¿¬±¸ÀÇ È°¼ºÈ­ ¹× ¹ßÀü¿¡ °øÇåÇϱâ À§ÇÏ¿© Àç´Ü¹ýÀÎ ´ëÇѾϿ¬±¸Àç´Ü¿¡¼­´Â Á¦9ȸ "±èÁøº¹ ¾Ï¿¬±¸»ó"À» °ø¸ðÇÕ´Ï´Ù. ¾Ï ¿¬±¸ ºÐ¾ß¿¡¼­ ±¹Á¦ÀûÀÎ ¾÷ÀûÀ» ÀÌ·ç°í, ±¹³» ¾Ï ¿¬±¸ ¹ßÀü¿¡ ±â¿©ÇÑ ¿¬±¸ÀÚ¸¦ ¼±Á¤ÇÏ¿© ½Ã»óÇÏ°íÀÚ ÇÏ¿À´Ï ¿¬±¸ÀÚ ¿©·¯ºÐÀÇ ¸¹Àº ½Åû ¹Ù¶ø´Ï´Ù. ¢ÃÀÚ °Ý ¾Ï¿¡ °üÇÑ ¿ì¼öÇÑ ¿¬±¸ ³í¹®À» ¹ßÇ¥ÇÑ ÀÚ (Á¦1ÀúÀÚ È¤Àº ±³½ÅÀúÀÚÀ̾î¾ß ÇÑ´Ù) ¢Ã½Åû¼­·ù ¨ç ½Åû ¹× Ãßõ¼­ : ½Åû ¾ç½ÄÀº ´ëÇѾϿ¬±¸Àç´Ü ȨÆäÀÌÁö http://Koreanfcr.or.kr/ ¸¦ ÂüÁ¶. °³º° ¹®ÀÇ´Â TEL: 02-747-0224 ¶Ç´Â E-MAIL: Koreanfcr@daum.net À¸·Î ¹®ÀÇ. ÃßõÀÎÀº ÇÐȸÀå ¶Ç´Â ¼Ò¼Ó ¿¬±¸¼ÒÀå ¹× ±â°üÀå À̾î¾ß ÇÔ. ¨è ½É»ç´ë»ó ÁÖ ³í¹® Ã¥ 10ºÎ Á¦Ãâ : ³í¹®Àº 2012³â 7¿ù 1ÀϺÎÅÍ 2014³â 6¿ù 30ÀÏ ±â°£ ³» ±¹Á¦ ÇмúÁö¿¡¼­ ¹ßÇ¥µÈ °ÍÀ¸·Î, ±¹³»¿¡¼­ ¼öÇàÇÑ ¿¬±¸À̾î¾ß ÇÔ. ¿Ü±¹¿¡¼­ ¼öÇà µÈ ³í¹®ÀÎ °æ¿ì ½É»ç¿¡¼­ Á¦¿Ü. ¨é ½Åû ¹× Ãßõ¼­, ³í¹® ÆÄÀÏÀ» º°µµ·Î E-MAIL: Koreanfcr@daum.net ·Î Á¢¼ö ¢Ã½É »ç ´ëÇѾϿ¬±¸Àç´Ü¿¡¼­ À§ÃËÇÑ ½É»çÀ§¿ø ¢Ã½Ã»ó³»¿ë »óÀå ¹× »ó±Ý 3000¸¸¿ø ¢Ã½Ã»óÀÏ Á¦24Â÷ ¼­¿ï±¹Á¦¾Ï½ÉÆ÷Áö¿ò ¼®»ó(2014. 12. 13(Åä) ¿ÀÈÄ 1½Ã~ , ¼­¿ïÀÇ´ë ¾Ï¿¬±¸¼Ò ÀÌ°ÇÈñȦ) Á¦9ȸ ±èÁøº¹ ¾Ï¿¬±¸»ó ¼ö»óÀÚ´Â Á¦24Â÷ ¼­¿ï±¹Á¦¾Ï½ÉÆ÷Áö¿ò¿¡ º»ÀÎÀÌ Âü¼®ÇÏ¿© ¼ö»ó³í¹® ÁÖÁ¦¹ßÇ¥¸¦ ÇÏ¿©¾ß ÇÕ´Ï´Ù. ¢Ã½Åû±âÇÑ 2014³â 10¿ù 24ÀÏ(±Ý)±îÁö µµÂøµÈ ½Åû¼­·ù¿¡ ÇÑÇÔ ¢ÃÁ¢¼öó ¿ìÆíÁ¢¼ö : ¼­¿ï½Ã Á¾·Î±¸ ´ëÇзΠ103 ¼­¿ï´ëÇб³ ¾Ï¿¬±¸¼Ò 1Ãþ 109-2È£ (Àç)´ëÇѾϿ¬±¸Àç´Ü (¿ì) 110-799 À̸ÞÀÏ Á¢¼ö : Koreanfcr@daum.net (¿ìÆí, À̸ÞÀÏ ¸ðµÎ Á¢¼öÇÏ¿©¾ß ÇÔ. À̸ÞÀÏ Á¢¼ö ½Ã ÃßõÀÎ Á÷ÀÎ ºÒÇÊ¿ä) ¢Ã Á¦1ȸ ±èÁøº¹¾Ï¿¬±¸»ó ¼ö»óÀÚ : ¼­¿ï´ë ÀÚ¿¬°úÇдëÇÐ »ý¸í°úÇкΠ¹é¼ºÈñ ±³¼ö ¡°Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes¡± ¢Ã Á¦2ȸ ±èÁøº¹¾Ï¿¬±¸»ó ¼ö»óÀÚ : ¼­¿ï´ë ÀÇ°ú´ëÇÐ »ýÈ­Çб³½Ç/¾Ï¿¬±¸¼Ò À±È«´ö ±³¼ö ¡°p53 stabilization and transactivation by a von Hippel-Lindau protein¡± ¢Ã Á¦3ȸ ±èÁøº¹¾Ï¿¬±¸»ó ¼ö»óÀÚ : ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÇаú ¾Ï¿¬±¸¼Ò ÀÌÁ¤¿ø ±³¼ö ¡°Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma¡± ¢Ã Á¦4ȸ ±èÁøº¹¾Ï¿¬±¸»ó ¼ö»óÀÚ : ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çаú ±è¿ìÈ£ ±³¼ö ¡°Protein expression profiling and molecular classification of gastric cancer by the tissue array method¡± ¢Ã Á¦5ȸ ±èÁøº¹ ¾Ï¿¬±¸»ó ¼ö»óÀÚ : ±¹¸³¾Ï¼¾ÅÍ ºÎ¼Ó ¾ç¼ºÀÚÄ¡·á¼¾ÅÍ, Àڱþϼ¾ÅÍ ±èÁÖ¿µ ¡° Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy¡± : ±¹¸³¾Ï¼¾ÅÍ À¯¹æ¾Ï¼¾ÅÍ / ÀÓ»ó½ÃÇè¼¾ÅÍÀå ³ëÁ¤½Ç ¡° Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy¡± ¢Ã Á¦6ȸ ±èÁøº¹ ¾Ï¿¬±¸»ó ¼ö»óÀÚ : ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç ¹æ¿µÁÖ ±³¼ö "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial". Lancet, 2010;376(9742):687-97 ¢Ã Á¦7ȸ ±èÁøº¹ ¾Ï¿¬±¸»ó ¼ö»óÀÚ ÇØ´ç ¼ö»óÀÚ ¾øÀ½. ¢Ã Á¦8ȸ ±èÁøº¹¾Ï¿¬±¸»ó ¼ö»óÀÚ : ÀüºÏ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¼ÒÈ­±â³»°ú ±è´ë°ï ±³¼ö ¡°Activation of Mammalian Target of Rapamycin Complex 1 (mTORC1) and Raf/Pyk2 by Growth Factor-Mediated Eph Receptor 2 (EphA2) Is Required for Cholangiocarcinoma Growth and Metastasis. Hepatology, 2013;57(6): 2248-2260 ** ÷ºÎ : ¿ä°­ ¹× ½Åû¼­